Dabigatran

Generic Name: Dabigatran

Brand Names: Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₅N_₇O_₃

CAS Number: 211914-51-1

Unique Ingredient Identifier: I0VM4M70GC

Background: Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease

Phase 4

Completed

Conditions: Coronary Disease

Interventions: Drug: Dabigatran
Drug: Enoxaparin

First Posted Date: 2015-03-17

Last Posted Date: 2016-04-29

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 29

Registration Number: NCT02389582

Locations: 🇧🇷
InCor Heart Institute, São Paulo, Brazil

Dabigatran in an Interaction Probe Drug Cocktail

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Caffeine
Drug: Diclofenac
Drug: Esomeprazole
Drug: Metoprolol
Drug: Midazolam
Drug: Dabigatran
Drug: Clarithromycin

First Posted Date: 2015-02-12

Last Posted Date: 2018-08-14

Lead Sponsor: Turku University Hospital

Target Recruit Count: 16

Registration Number: NCT02361619

Locations: 🇫🇮
Teutori CPRU, Turku, Finland

Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran

Phase 4

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban
Drug: Dabigatran

First Posted Date: 2015-01-06

Last Posted Date: 2015-08-06

Lead Sponsor: Yokohama City University Medical Center

Target Recruit Count: 200

Registration Number: NCT02331602

Locations: 🇯🇵
Omori Red Cross Hospital, Ohta, Tokyo, Japan
🇯🇵
International Goodwill Hospital, Yokohama, Kanagawa, Japan
🇯🇵
Yokohama City University Hospital, Yokohama, Kanagawa, Japan

and more 13 locations

Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk

Phase 3

Conditions: Atrial Fibrillation
Thromboembolism

Interventions: Drug: dabigatran
Drug: placebo

First Posted Date: 2014-12-10

Last Posted Date: 2014-12-10

Lead Sponsor: Korea University

Target Recruit Count: 464

Registration Number: NCT02313584

Dabigatran Following Transient Ischemic Attack and Minor Stroke

Phase 2

Completed

Conditions: Transient Ischemic Attack
Minor Ischemic Stroke

Interventions: Drug: Acetylsalicylic acid
Drug: Dabigatran

First Posted Date: 2014-11-20

Last Posted Date: 2019-01-30

Lead Sponsor: University of Alberta

Target Recruit Count: 300

Registration Number: NCT02295826

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

and more 3 locations

Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: dabigatran

First Posted Date: 2014-08-22

Last Posted Date: 2016-09-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02223260

Locations: 🇫🇷
1160.105.33001 Boehringer Ingelheim Investigational Site, Paris, France
🇨🇦
1160.105.10002 Boehringer Ingelheim Investigational Site, Ottawa, Ontario, Canada
🇨🇦
1160.105.10003 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada

and more 1 locations

Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: dabigatran
Drug: Verapamil
Drug: Verapamil ER

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02171533

Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran
Drug: Atorvastatin

First Posted Date: 2014-06-23

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02171039

Drug Interaction Study Between Bosutinib And Dabigatran

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran
Drug: Bosutinib

First Posted Date: 2014-04-03

Last Posted Date: 2014-06-24

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT02102633

Locations: 🇺🇸
Pfizer Investigational Site, DeLand, Florida, United States

Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Not Applicable

Conditions: Hip Osteoarthritis
Blood Loss

Interventions: Drug: Enoxaparin
Drug: dabigatran
Drug: rivaroxaban

First Posted Date: 2014-03-13

Last Posted Date: 2014-03-14

Lead Sponsor: Centre of Postgraduate Medical Education

Target Recruit Count: 60

Registration Number: NCT02085824

Locations: 🇵🇱
Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education, Otwock, Woj. Mazowieckie, Poland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy